{"entity":{"id":"aall1521","kind":"trial","name":"AALL1521","aka":["COG AALL1521","INCB 18424-269"],"tldr":"AALL1521 is the trial that added the JAK-blocking pill ruxolitinib to chemotherapy for children whose leukaemia looks like Philadelphia-positive disease but is driven by JAK signalling; it has finished treating patients and the survival results are awaited.","summary":"AALL1521 is a single-arm phase 2 study run by Incyte with the Children's Oncology Group in children and young adults with newly diagnosed high-risk B-cell acute lymphoblastic leukaemia that is Philadelphia chromosome-like with a CRLF2 rearrangement or a JAK pathway mutation, or with other JAK-STAT activating lesions. Ruxolitinib was added to the AALL1131 high-risk chemotherapy backbone from consolidation onwards. Part 1 established the safe dose and schedule; Part 2 measures three-year event-free survival in each genetic cohort.\n\nThe study enrolled 171 patients and is recorded as completed with a primary completion date of March 2026. No primary results have been posted on the registry or published in a journal indexed by Europe PMC, so the corpus records what the trial tests and not a result. The Philadelphia-like leukaemia page cites it as the trial through which ruxolitinib is being added to chemotherapy.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02723994","url":"https://clinicaltrials.gov/study/NCT02723994"}],"tags":["soc-trials"],"related":[],"cancers":["all-ph-like","all-leukemia","leukaemia"],"sections":[],"technologies":["kinase-inhibitors","cytotoxic-chemotherapy"],"targets":[],"drugs":["ruxolitinib"],"companies":["incyte"],"institutions":["childrens-oncology-group"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02723994","phase":"2","setting":"Children and young adults with newly diagnosed high-risk Philadelphia chromosome-like B-cell acute lymphoblastic leukaemia carrying a CRLF2 rearrangement or a JAK pathway mutation: the JAK1 and JAK2 inhibitor ruxolitinib added to post-induction chemotherapy, in a dose-finding part and an efficacy part with three-year event-free survival as the endpoint","sponsor":"Incyte Corporation","enrolled":171,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/aall1521/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"institution":[{"id":"childrens-oncology-group","kind":"institution","name":"Children's Oncology Group (COG)","route":"/institutions/childrens-oncology-group/"}]}}